← My Government dashboard

Government Watch

Dossier Executive final rule 17-jun-2026 Takes effect · 17-jun-2026
Finalized regulation — legally enforceable once its effective date arrives.

Medical Devices; Gastroenterology-Urology Devices; Classification of the Ingestible Gastrointestinal Blood Detection Capsule

Key claim: The FDA is classifying the ingestible gastrointestinal blood detection capsule as a class II medical device subject to special controls, determining this provides reasonable assurance of safety and effectiveness while enhancing patient access.

Abstract

(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the ingestible gastrointestinal blood detection capsule into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the ingestible gastrointestinal blood detection capsule. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.

Why this matters

Formal Class II classification establishes a defined regulatory pathway for ingestible GI blood detection capsules, meaning future manufacturers can rely on special controls rather than premarket approval to bring similar devices to market. For patients and providers, this may expand access to non-invasive alternatives to endoscopy for detecting GI bleeding.

Source

Link

Briefing card

Medical Devices; Gastroenterology-Urology Devices; Classification of the Ingestible Gastrointestinal Blood Detection Capsule
Stage: final rule · federal-register · 17-jun-2026

The FDA is classifying the ingestible gastrointestinal blood detection capsule as a class II medical device subject to special controls, determining this provides reasonable assurance of safety and effectiveness while enhancing patient access.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: fedreg:2026-12165

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Stages other doctrine resolution introduced proposed rule passed chamber executive action final rule enacted district opinion circuit opinion opinion

build build 392 · ea9c128-dirty · 2026-08-09